Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: Robatumumab
Drug: Irinotecan
Biological: Cetuximab
Drug: Capecitabine
Drug: FOLFOX
Drug: CAPEOX/XELOX
Drug: FOLFIRI

First Posted Date: 2007-10-30

Last Posted Date: 2018-08-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 67

Registration Number: NCT00551213

High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Dietary Supplement: high-selenium Brassica juncea
Drug: capecitabine
Drug: irinotecan hydrochloride

First Posted Date: 2007-10-22

Last Posted Date: 2015-11-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 22

Registration Number: NCT00547547

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
South Pasadena Cancer Center, Pasadena, California, United States

Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer

Phase 2

Conditions: Small Cell Lung Cancer

Interventions: Drug: Irinotecan hydrochloride
Drug: Cisplatin
Drug: Krestin

First Posted Date: 2007-10-18

Last Posted Date: 2008-09-03

Lead Sponsor: University of Toyama

Target Recruit Count: 45

Registration Number: NCT00546130

Locations: 🇯🇵
Osaka Medikal College Hospital, Takatsuki, Osaka, Japan
🇯🇵
Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
🇯🇵
Toyama University Hospital, Toyama, Japan

and more 12 locations

Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

First Posted Date: 2007-10-16

Last Posted Date: 2011-06-27

Lead Sponsor: Hopital Jean Minjoz

Target Recruit Count: 47

Registration Number: NCT00544011

Locations: 🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France

Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma

Phase 2

Terminated

Conditions: Sarcoma

Interventions: Biological: filgrastim
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: irinotecan hydrochloride
Genetic: protein expression analysis
Other: immunoenzyme technique
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy